... continue developing its lead gene therapy candidate HMI-102, for treatment of phenylketonuria in adults, which is currently in Phase 2 clinical trial.
https://www.google.com/url?rct=j&sa=t&url=https://www.investorsobserver.com/news/stock-update/homology-medicines-down-18-after-announcing-common-stock-offering&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNGwdCPhs116Fw8ieeoHw7vh_-X6kA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.